Pemetrexed and cisplatin combination with concurrent whole brain radiotherapy in patients with brain metastases of lung adenocarcinoma: a single-arm phase II clinical trial

2013 ◽  
Vol 112 (3) ◽  
pp. 461-466 ◽  
Author(s):  
Xiao-xiao Dinglin ◽  
Yan Huang ◽  
Hui Liu ◽  
Yin-duo Zeng ◽  
Xue Hou ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Brain Metastases ◽  
Lung Adenocarcinoma ◽  
Phase Ii ◽  
Whole Brain Radiotherapy ◽  
Phase Ii Clinical Trial ◽  
Whole Brain ◽  
Brain Radiotherapy

scholarly journals Hippocampal avoidance whole-brain radiotherapy without memantine in preserving neurocognitive function for brain metastases: a phase II blinded randomized trial

2020 ◽  
Author(s):  
Wen-Chi Yang ◽  
Ya-Fang Chen ◽  
Chi-Cheng Yang ◽  
Pei-Fang Wu ◽  
Hsing-Min Chan ◽  
...  
Keyword(s):  
Brain Metastases ◽  
Phase Ii ◽  
Whole Brain Radiotherapy ◽  
Neurocognitive Function ◽  
Mean Difference ◽  
Whole Brain ◽  
Delayed Recall ◽  
Brain Radiotherapy ◽  
Hippocampal Avoidance

Abstract Background Hippocampal avoidance whole-brain radiotherapy (HA-WBRT) shows potential for neurocognitive preservation. This study aimed to evaluate whether HA-WBRT or conformal WBRT (C-WBRT) is better for preserving neurocognitive function. Methods This single-blinded randomized phase II trial enrolled patients with brain metastases and randomly assigned them to receive HA-WBRT or C-WBRT. Primary endpoint is decline of the Hopkins Verbal Learning Test–Revised (HVLT-R) delayed recall at 4 months after treatment. Neurocognitive function tests were analyzed with a mixed effect model. Brain progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan–Meier method. Results From March 2015 to December 2018, seventy patients were randomized to yield a total cohort of 65 evaluable patients (33 in the HA-WBRT arm and 32 in the C-WBRT arm) with a median follow-up of 12.4 months. No differences in baseline neurocognitive function existed between the 2 arms. The mean change of HVLT-R delayed recall at 4 months was −8.8% in the HA-WBRT arm and +3.8% in the C-WBRT arm (P = 0.31). At 6 months, patients receiving HA-WBRT showed favorable perpetuation of HVLT-R total recall (mean difference = 2.60, P = 0.079) and significantly better preservation of the HVLT-R recognition-discrimination index (mean difference = 1.78, P = 0.019) and memory score (mean difference = 4.38, P = 0.020) compared with patients undergoing C-WBRT. There were no differences in Trail Making Test Part A or Part B or the Controlled Oral Word Association test between the 2 arms at any time point. There were no differences in brain PFS or OS between arms as well. Conclusion Patients receiving HA-WBRT without memantine showed better preservation in memory at 6-month follow-up, but not in verbal fluency or executive function.

scholarly journals Hair-sparing whole brain radiotherapy with volumetric arc therapy in patients treated for brain metastases: dosimetric and clinical results of a phase II trial

2014 ◽  
Vol 9 (1) ◽  
pp. 170 ◽  
Author(s):  
Annemieke De Puysseleyr ◽  
Joris Van De Velde ◽  
Bruno Speleers ◽  
Tom Vercauteren ◽  
Anneleen Goedgebeur ◽  
...  
Keyword(s):  
Brain Metastases ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Whole Brain Radiotherapy ◽  
Clinical Results ◽  
Whole Brain ◽  
Brain Radiotherapy ◽  
Volumetric Arc Therapy ◽  
Arc Therapy

A phase II prospective study of standardized steroid dosing for patients with brain metastases undergoing whole brain radiotherapy

2008 ◽  
Vol 26 (15_suppl) ◽  
pp. 2050-2050
Author(s):  
A. E. Sturdza ◽  
A. Bezjak ◽  
G. R. Pond ◽  
K. Brrows ◽  
B. Millar ◽  
...  
Keyword(s):  
Brain Metastases ◽  
Prospective Study ◽  
Phase Ii ◽  
Whole Brain Radiotherapy ◽  
Whole Brain ◽  
Brain Radiotherapy

scholarly journals Whole Brain Radiotherapy and RRx-001: Two Partial Responses in Radioresistant Melanoma Brain Metastases from a Phase I/II Clinical Trial

2016 ◽  
Vol 9 (2) ◽  
pp. 108-113 ◽  
Author(s):  
Michelle M. Kim ◽  
Hemant Parmar ◽  
Yue Cao ◽  
Priyanka Pramanik ◽  
Matthew Schipper ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Brain Metastases ◽  
Phase I ◽  
Whole Brain Radiotherapy ◽  
Whole Brain ◽  
Brain Radiotherapy ◽  
Melanoma Brain Metastases

Temozolomide and concomitant whole brain radiotherapy in patients with brain metastases: A phase II randomized trial

2005 ◽  
Vol 61 (1) ◽  
pp. 185-191 ◽  
Author(s):  
Eugènia Verger ◽  
Miguel Gil ◽  
Ricardo Yaya ◽  
Núria Viñolas ◽  
Salvador Villà ◽  
...  
Keyword(s):  
Brain Metastases ◽  
Randomized Trial ◽  
Phase Ii ◽  
Whole Brain Radiotherapy ◽  
Whole Brain ◽  
Brain Radiotherapy
Sign in / Sign up

Export Citation Format

Share Document